Pankaj Patel said this would simplify the processes and improve ease of doing business
President-elect Donald Trump has announced that creating jobs would be the cornerstone of his presidency and took aim at the pharmaceutical sector vowing to bring the industry back to the US.
Gujarat houses nearly 135 licensed medical devices manufacturers in the country
The S&P BSE Healthcare index was up 2.4% as compared to 1.5% rise in the S&P BSE Sensex at 02:55 pm
Dr Reddys, Sun Pharma, Lupin, Glenmark Pharma and Cadila Healthcare were down between 4% and 5% on the NSE.
Strides Shasun, Jubilant Life Sciences and Sun Pharma Advanced Research were up between 5% and 12%.
Total amount these firms owe to government is around Rs 3,500 crore
Aurobindo, Glenmark, Natco see strong domestic and US growth, which should reflect in results
Digital platforms are making it simpler for the drug companies to communicate with doctors
Company has made an investment to the tune of Rs 321.44 crore in FY16 to set up two new state-of-the-art manufacturing facilities
The idea behind a uniform code is to ensure fair marketing in the sector. Medical device makers, too, will have to comply
Sequent Scientific, Torrent Pharma, Hikal, Ipca Lab and Aurobindo Pharma were up between 5%-20% on the BSE.
Already several mid-sized cos have started scouting land; state govt setting up pharma and medical devices park; bets on existing eco-system
Low growth visibility and trouble with regulators have resulted in lack of interest from investors
Savings to consumers on account of revision and price fixing of essential drugs amounted to Rs 4,988 crore in the last two years
FDI policy provides for 100 per cent FDI under automatic route in greenfield pharma
Nirmala Sitharaman said there was a slowdown in exports from SEZs because of reasons like withdrawal of exemptions of minimum alternate tax
Aurobindo Pharma, Cipla, Cadila and Sun Pharma from the Nifty Pharma index were up 1% each on the NSE.
Pharmaceutical and select automobile stocks, impacted by Britain's exit from the European Union (Brexit), have recouped their losses and are trading higher than the levels they were trading a day prior to the result."The exposure of these firms to Europe is eight-10 per cent of the total exports, so the impact is likely to be contained," said G Chokkalingam, founder, Equinomics Research. The rally has also aided the recovery.The information technology pack, however, continues to languish with key stocks trading one-five per cent below the pre-Brexit level."IT will take some time to recover as a lot of contracts are up for renewal and buyers in the euro region might want to postpone their decision till clarity emerges," said Deven Choksey, managing director, KR Choksey Shares.Tata group companies have a large exposure in the UK and EU, and Tata Motors and Tata Steel are also below the pre-Brexit levels.
Dr Reddy's, Lupin, Cipla, Marksans Pharma, Sanofi India, Aurobindo and JB Chemicals gain over 5% each in one week.